RANA, JATINDER,拉那 贾提达尔,拉那 賈提達爾,RANDOLPH, RUSSELL KEITH,兰道夫 鲁塞尔K,蘭道夫 魯塞爾K,SCHOLTEN, JEFFREY,萧尔顿 杰佛瑞,蕭爾頓 傑佛瑞,LE, MYPHUONG THI,黎 美芳T,黎 美芳T,JOHNSON, RICHARD J.,强森 理察J,強森 理察J,LANASPA GARCIA, MIGUEL ANGEL,拉
申请号：
TW103121028
公开号：
TW201534315A
申请日:
2014.06.18
申请国别(地区):
TW
年份:
2015
代理人:
摘要：
A composition for inhibiting ketohexokinase, for example, ketohexokinase-C (KHK-C) activity, may include a plant extract exhibiting at least IC50 (i.e., 50% KHK-C inhibition at a concentration in the range of from about 0.1 μg/mL to about 1000 μg/mL. The composition may be in a form suitable for oral ingestion. A method for inhibiting KHK-C activity in a subject may include administering a plant extract that exhibits at least 50% KHK-C inhibition at a concentration from about 0.1 μg/mL to about 1000 μg/mL. The administering may be done to treat or prevent at least one of sugar addiction, obesity, or metabolic syndrome. The administering may be done to provide a diminished craving in the subject from at least one member selected from the group consisting of craving of sugar, fructose, fructose-containing sugars, carbohydrates, and combinations thereof. The subject may be pre-diabetic, diabetic and or insulin resistant.一種用於抑制己酮糖激酶之組成物,舉例而言,己酮糖激酶-C(KHK-C)活性,該組成物可能包括一植物萃取物其展現至少IC50(意即至少50%KHK-C抑制在從約0.1μg/mL至約1000μg/mL之一濃度)。該組成物可能是呈適於口服攝入的形式。一種在個體中抑制KHK-C活性的方法,該方法可能包括投藥一植物萃取物,其在0.1μg/mL至約1000μg/mL之一濃度下展現至少50%KHK-C抑制。該投藥可能執行以治療或預防糖成癮、肥胖或代謝症侯群中至少一種。該投藥可能執行以在該個體提供一減少的渴求,該渴求是針對選自由糖、果糖、含果糖的糖類、碳水化合物、及其等之組合所組成之群組中之至少一者。個體可能處於糖尿病前期、患糖尿病的及/或具胰島素抗性的。
